Spiro compounds containing five-membered rings
OwnerAbraham Fisher, Yishai Karton +3inventors
InventorsAbraham Fisher, Yishai Karton, Daniele Marciano, Dov Barak, Haim Meshulam
Life of this patent
Estimating the term…
Abstract
Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XIII: ##STR1## wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.
Claims32
A compound having muscarinic activity and which is selected form the group consisting of:
- 1-methylpiperidine-4-spiro-5'-(3'-ethylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(1'-acetylhydantoin),
- piperidine-4-spiro-5'-(3'-ethylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-methylhydantoin),
- piperidine-4-spiro-5'-(3'-methylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-propargylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyl-4'-thiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(4'-methylthio-3'-imidazoline-2'-thione),
- 1-methylpiperidine-4-spiro-5'-(2',4'-dithiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyl-2',4'-dithiohydantoin),
- 1-methylpiperdine-4-spiro-5'-(4'-ethylthio-3'-imidazoline-2'-thione),
- 1-methylpiperidine-4-spiro-4'-(1'-ethyl-2'-ethylthio-2'-imidazoline-5'-thio ne),
- 1-methylpiperidine-4-spiro-5'-(2'-thiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(2'-thio-4'-.beta.-hydroxyethyliminohydantoin ),
- 1-methylpiperidine-4-spiro-5'-(oxazolidine-2'-thione),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyloxazolidine-2'-one),
- 1-methylpiperidine-4-spiro-4'-(3'ethyloxazolidine-2'-one),
- 1-methylpiperidine-4-spiro-4'-(2'-methyl-2'-thiazoline),
- 1-methylpiperidine-4-spiro-4'(5')-(2'-methyl-2'-imidazoline),
- 1-methylpiperidine-4-spiro-5'-(2'-methyl-2'-oxazoline-4'-one), and their pharmaceutically acceptable salts, quaternary compounds, enantiomers and racemates.
A pharmaceutical composition for use in treating disease of the central and peripheral nervous system in mammals, which comprises an amount effective for use in treating said diseases, of a compound having muscarinic activity and which is selected from the group consisting of:
- 1-methylpiperidine-4-spiro-5'-(3'-ethylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(1'-acetylhydantoin),
- piperidine-4-spiro-5'-(3-ethylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-methylhydantoin),
- piperidine-4-spiro-5'-(3'-methylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-propargylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyl-4'-thiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(4'-methylthio-3'-imidazoline-2'-thione),
- 1-methylpiperidine-4-spiro-5'-(2',4'-dithiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyl-2',4'-dithiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(4'-ethylthio-3'-imidazoline-2'-thione),
- 1-methylpiperidine-4-spiro-4'-(1'-ethyl-2'-ethylthio-2'-imidazoline-5'-thio ne),
- 1-methylpiperidine-4-spiro-5'-(2'-thiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(2'-thio-4'-.beta.-hydroxyethyliminohydantoin ).
- 1-methylpiperidine-4-spiro-5'-(oxazolidine-2'-thione),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyloxazolidine-2'-one),
- 1-methylpiperidine-4-spiro-4'-(3'-ethyloxazolidine-2'-one),
- 1-methylpiperidine-4-spiro-4'-(2'-methyl-2'-thiazoline),
- 1-methylpiperidine-4-spiro-4'(5')-(2'-methyl-2'-imidazoline),
- 1-methylpiperidine-4-spiro-5'-(2'-methyl-2'-oxazoline-4'-one), and their pharmaceutically acceptable salts, quaternary compounds, enantiomers and racemates.
A method for treating diseases of the central or peripheral nervous system in mammals, which comprises administering to the mammal an amount effective for use in treating said diseases, of a compound having muscarinic activity and which is selected from the group consisting of:
- 1-methylpiperidine-4-spiro-5'-(3'-ethylhydantoin).
- 1-methylpiperidine-4-spiro-5'-(1'-acetylhydantoin),
- piperidine-4-spiro-5'-(3'-ethylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-methylhydantoin),
- piperidine-4-spiro-5'-(3'-methylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-propargylhydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyl-4'-thiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(4'-methylthio-3'-imidazoline-2'-thione),
- 1-methylpiperidine-4-spiro-5'-(2',4'-dithiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyl-2',4'-dithiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(4'-ethylthio-3'-imidazoline-2'-thione),
- 1-methylpiperidine-4-spiro-4'-(1'-ethyl-2'-ethylthio-2'-imidazoline-5'-thio ne),
- 1-methylpiperidine-4-spiro-5'-(2'-thiohydantoin),
- 1-methylpiperidine-4-spiro-5'-(2'-thio-4'-.beta.-hydroxyethyliminohydantoin ).
- 1-methylpiperidine-4-spiro-5'-(oxazolidine-2'-thione),
- 1-methylpiperidine-4-spiro-5'-(3'-ethyloxazolidine-2'-one),
- 1-methylpiperidine-4-spiro-4'-(3'-ethyloxazolidine-2'-one),
- 1-methylpiperidine-4-spiro-4'-(2'-methyl-2'-thiazoline),
- 1-methylpiperidine-4-spiro-4'(5')-(2'-methyl-2'-imidazoline),
- 1-methylpiperidine-4-spiro-5'-(2'-methyl-2'-oxazoline-4'-one), and their pharmaceutically acceptable salts, quaternary compounds, enantiomers and racemates.
Dependencies are inferred from the claim text.